Odronextamab - Regeneron Pharmaceuticals
Alternative Names: CD20xCD3 bispecific antibody - Regeneron Pharmaceuticals; Ordspono; REGN-1979; ZL-1307Latest Information Update: 29 Jan 2025
Price :
$50 *
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Diffuse large B cell lymphoma; Follicular lymphoma
- Phase III Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Phase I B-cell lymphoma; Chronic lymphocytic leukaemia
Most Recent Events
- 14 Jan 2025 University of Washington in collaboration with Regeneron Pharmaceuticals plan a phase II trial for Diffuse large B cell lymphoma (Second-line therapy or greater, Recurrent) in USA (IV) in April 2025 (NCT06784726)
- 09 Dec 2024 Regeneron Pharmaceuticals announces intention to file US FDA regulatory resubmission for odronextamab in Follicular lymphoma after two or more lines of systemic therapy in the first half of 2025.
- 09 Dec 2024 Efficacy and adverse event data from the phase III OLYMPIA-1 trial in Follicular lymphoma released by Regeneron Pharmaceuticals